Transdermal Patches Drug Delivery Articles & Analysis
15 news found
CD Formulation, a leading force in biotechnology research and development, is at the forefront of revolutionizing transdermal delivery systems. As the demand for non-invasive, efficient drug delivery systems grows, CD Formulation has announced its abilities in providing a few transdermal delivery enhancement technologies. Transdermal Delivery: Overcoming Natural Barriers Traditional transdermal ...
In today’s evolving pharmaceutical landscape, the search for new drug delivery systems (DDS) is of paramount importance to improving therapeutic outcomes. With cutting-edge solutions in the field of microneedle technology, Protheragen-ING is on the front lines in this field. As a certified ISO9001 supplier of pharmaceutical ingredients and specialty chemicals, Protheragen-ING keeps ...
The new technology represents a significant advancement in the field of transdermal drug delivery. The hydrogel microneedle patch consists of a patch with tiny microneedles made of hydrogel, which can deliver drugs directly into the skin. ...
This cutting-edge drug delivery system is poised to revolutionize medication administration, offering patients a more convenient and effective treatment method. ...
CD Formulation has been dedicated to pharmaceutical advancements, showcasing immense expertise in the development and optimization of micro-reservoir controlled-release drug delivery systems. These innovative systems have revolutionized the way medications are administered, enhancing patient comfort and ensuring optimal therapeutic efficacy. Transdermal drug delivery systems are very popular ...
With a relentless commitment to delivering innovative solutions and excellent customer service, CD Formulation has built a strong reputation in the industry, particularly in fields like Transdermal Patches Drug Delivery System, Oral Thin Films Drug Delivery, Microneedle Technology, Microsphere ...
Transdermal patches, yet another key service area of CD Formulation, provide controlled drug release through the skin. ...
CD Formulation, a reputable contract research organization (CRO) based in New York, has become a trusted partner for many pharmaceutical companies around the world seeking innovative drug formulation methods and solutions. Recently, CD Formulation further strengthened its role as a drug delivery expert by demonstrating its expertise in the ...
Since its launch, the pharmaceutical excipients provided by CD Formulation have gained significant popularity among customers worldwide. To enhance the search process, CD Formulation has recently reorganized its collection of pharmaceutical excipients and unveiled these changes on its website. With a focus on improving drug delivery systems and dosage forms, the company aims to offer innovative ...
The newly introduced solutions are focused on long-acting controlled-release microspheres and phase-transition microneedle patches, to meet the growing demand for novel biopharmaceuticals and biosimilars, while at the same time, improving efficacy, safety, and convenience in drug delivery. Microsphere and microneedle technologies have been ...
In the past decade, several new drug delivery systems have been formulated, in the hope to provide promising alternative routes to the current popular drug delivery systems. ...
Though the service portfolio of CD Formulation is far-ranged and nearly covers the whole process of drug formulation, encompassing pre-formulation, formulation, drug analysis, solubility improvement and bioavailability enhancement, packaging, drug delivery system development, one-stop pharmaceutical formulation solution as well ...
Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy and Safety Study of a Transdermal Alkalinizing and Pain Relieving Treatment for Acute Gout Pain Objectives: Gout is characterized by a build-up of monosodium urate (MSU) crystals in and around the joints. MSU crystal formation and dissolution is affected by pH. There are reports in the literature of the use of alkalization agents, ...
Dr. Ryan Gordon has joined the Stem Pharm team as Sr. V.P. of Business Development and Commercialization. Gordon brings to Stem Pharm over 20 years of business, R&D, and operational experience in developing and commercializing innovative biopharmaceutical technologies to revolutionize disease treatment and improve patient outcomes. He has been a valued leader at large companies (3M) and ...
Dyve Biosciences received FDA clearance to begin a Phase 2 study of its DYV-700 transdermal therapeutic for the treatment of acute gout pain. Thousand Oaks, Calif.-based Dyve said it plans to begin the Targets study in the first quarter of 2020. It is slated to be a double-blind, placebo-controlled, randomized clinical trial to evaluate the efficacy of DYV-700 in patients with acute gout flare. ...